enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Increase in Short Interest

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 2,192,033 shares, an increase of 52.2% from the January 15th total of 1,440,058 shares. Based on an average trading volume of 590,195 shares, the days-to-cover ratio is presently 3.7 days. Currently, 3.7% of the company’s stock are sold short. Currently, 3.7% of the company’s stock are sold short. Based on an average trading volume of 590,195 shares, the days-to-cover ratio is presently 3.7 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ENGN shares. Jefferies Financial Group started coverage on enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 price target for the company. Oppenheimer reiterated an “outperform” rating and set a $33.00 target price (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of enGene in a report on Wednesday, December 3rd. Finally, Citizens Jmp increased their price objective on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.00.

Hedge Funds Weigh In On enGene

Institutional investors have recently made changes to their positions in the stock. PFS Partners LLC bought a new stake in shares of enGene in the 3rd quarter worth approximately $61,000. Cresset Asset Management LLC bought a new position in enGene during the 2nd quarter worth $36,000. Raymond James Financial Inc. increased its position in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the period. Paloma Partners Management Co bought a new stake in enGene in the second quarter valued at $38,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of enGene during the third quarter valued at $76,000. 64.16% of the stock is owned by institutional investors.

enGene Stock Performance

Shares of NASDAQ ENGN traded down $0.16 during trading on Friday, reaching $9.78. The stock had a trading volume of 136,819 shares, compared to its average volume of 458,987. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a market cap of $655.16 million, a PE ratio of -4.27 and a beta of -0.29. enGene has a one year low of $2.65 and a one year high of $12.25. The firm’s 50 day moving average price is $9.24 and its two-hundred day moving average price is $7.37.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). On average, research analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.